Adaptimmune Therapeutics plc (NASDAQ:ADAP) currently has a daily average trading volume of 785.98K but it saw 1044803 shares traded on Wednesday. With a market cap of 1.19B USD, stock’s current market price of $1.20 came falling about -1.64 while comparing to the previous closing price of $1.22. In past 52 weeks, the stock remained buoying in the range of price level as high as $2.65 and as low as $1.01. In the recent trading on the day, stock has struck highest price mark of $1.24 while lowest mark touched by it was $1.15.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Taking a look at 20-day trading activity of Adaptimmune Therapeutics plc (ADAP) gives us an average price of $1.3530, while its current price level is -54.72% below from 52-week high level whereas it is 18.81% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.2582 while that of 200 days or SMA-200 reads an average of $1.5807. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.60% during that period while stretching the period over a month that decreases to 5.66%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 36.13 which implies that the stock is in neutral territory.
Over the week, ADAP’s stock price is moving -10.45% down while it is -9.09% when we observe its performance for the past one month. Year-to-date it is -17.81% down and over the past year, the stock is showing a downside performance of -20.53%.
The latest quarterly earnings report issued by the company was for quarter ended 3/30/2023, when its quarterly earnings per share (EPS) of $0.01 beat the consensus estimate of -$0.14 for the same. The company is expected to be releasing its next quarterly report in 08/03/2023, for which analysts forecasted an EPS of -$0.13 while estimate for next year EPS is -$0.41. For ADAP, analysts are forecasting an EPS-growth rate of 59.80% for current year and estimate for EPS growth in next year is -31.70%. In next quarter, company is expected to be making quarterly sales of $11.16 million as analysts are expecting the sales for current fiscal year at $81.05 million and seeing the company making $31.04 million in sales next year. Moreover, analysts are in estimates of $8.78 million for current-quarter revenue.
Currently, Adaptimmune Therapeutics plc’s total number of outstanding shares is 994.24M with 0.32% of that held by the insiders while 70.03% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -203.30% and return on equity (ROE) at -108.50%. Stock’s beta reads 2.26. Stock has a price to book (P/B) ratio of 2.35 while price to sale or P/S ratio amounts to 16.76. Its return on asset (ROA) is -34.10% on average.
In the most recent quarter, Old Westbury Small & Mid Cap Stra came rising its stake by 34.92% in the company and now holds 2.4 million or 1.46% of the company’s stake having worth of about 3.41 million.
Leave a Reply